FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103258308> ?p ?o ?g. }

• W2103258308 endingPage "1454" @default.
• W2103258308 startingPage "1451" @default.
• W2103258308 abstract "Objective. To follow-up on all available infliximab-treated SLE patients for safety and long-term efficacy in order to extract information that is useful for planning appropriate controlled trials with infliximab in SLE. Methods. We analysed charts of six patients treated in an open-label safety trial and seven additional patients treated with infliximab on a compassionate care basis for uncontrolled SLE organ inflammation. Results. Out of nine patients with lupus nephritis, six had a long-term response after four infusions of infliximab in combination with AZA, lasting for up to 5 years. All five patients with lupus arthritis responded, but this response did not last for >2 months after the last infusion. One additional patient had a long-lasting improvement in SLE interstitial lung disease. No symptoms suggestive of infliximab-induced SLE flares occurred in any patients. Short-term treatment appeared relatively safe, but one patient developed deep-vein thrombosis and several infections. Under long-term therapy, two patients had life-threatening or fatal events, namely CNS lymphoma and Legionella pneumonia. Retreatment and treatment without concomitant immunosuppression led to drug reactions. Conclusions. Short-term therapy with four infusions of infliximab in combination with AZA was relatively safe, and had remarkable long-term efficacy for lupus nephritis and, potentially, also interstitial lung disease. Long-term therapy with infliximab, however, was associated with severe adverse events in two out of three SLE patients, which may have been provoked by infliximab and/or by their long-standing refractory SLE and previous therapies." @default.
• W2103258308 created "2016-06-24" @default.
• W2103258308 creator A5004962774 @default.
• W2103258308 creator A5006821996 @default.
• W2103258308 creator A5027317477 @default.
• W2103258308 creator A5034229428 @default.
• W2103258308 creator A5042283831 @default.
• W2103258308 creator A5066602987 @default.
• W2103258308 creator A5072487328 @default.
• W2103258308 creator A5091190600 @default.
• W2103258308 date "2009-09-11" @default.
• W2103258308 modified "2023-10-18" @default.
• W2103258308 title "Adverse events and efficacy of TNF- blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients" @default.
• W2103258308 cites W1518420099 @default.
• W2103258308 cites W1968081199 @default.
• W2103258308 cites W1980449105 @default.
• W2103258308 cites W1981494429 @default.
• W2103258308 cites W1998033779 @default.
• W2103258308 cites W2008489937 @default.
• W2103258308 cites W2020462668 @default.
• W2103258308 cites W2024308747 @default.
• W2103258308 cites W2052688737 @default.
• W2103258308 cites W2070527591 @default.
• W2103258308 cites W2077017142 @default.
• W2103258308 cites W2080147816 @default.
• W2103258308 cites W2089737288 @default.
• W2103258308 cites W2091391560 @default.
• W2103258308 cites W2094313417 @default.
• W2103258308 cites W2107871522 @default.
• W2103258308 cites W2108529019 @default.
• W2103258308 cites W2123705157 @default.
• W2103258308 doi "https://doi.org/10.1093/rheumatology/kep270" @default.
• W2103258308 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19748965" @default.
• W2103258308 hasPublicationYear "2009" @default.
• W2103258308 type Work @default.
• W2103258308 sameAs 2103258308 @default.
• W2103258308 citedByCount "171" @default.
• W2103258308 countsByYear W21032583082012 @default.
• W2103258308 countsByYear W21032583082013 @default.
• W2103258308 countsByYear W21032583082014 @default.
• W2103258308 countsByYear W21032583082015 @default.
• W2103258308 countsByYear W21032583082016 @default.
• W2103258308 countsByYear W21032583082017 @default.
• W2103258308 countsByYear W21032583082018 @default.
• W2103258308 countsByYear W21032583082019 @default.
• W2103258308 countsByYear W21032583082020 @default.
• W2103258308 countsByYear W21032583082021 @default.
• W2103258308 countsByYear W21032583082022 @default.
• W2103258308 countsByYear W21032583082023 @default.
• W2103258308 crossrefType "journal-article" @default.
• W2103258308 hasAuthorship W2103258308A5004962774 @default.
• W2103258308 hasAuthorship W2103258308A5006821996 @default.
• W2103258308 hasAuthorship W2103258308A5027317477 @default.
• W2103258308 hasAuthorship W2103258308A5034229428 @default.
• W2103258308 hasAuthorship W2103258308A5042283831 @default.
• W2103258308 hasAuthorship W2103258308A5066602987 @default.
• W2103258308 hasAuthorship W2103258308A5072487328 @default.
• W2103258308 hasAuthorship W2103258308A5091190600 @default.
• W2103258308 hasBestOaLocation W21032583081 @default.
• W2103258308 hasConcept C126322002 @default.
• W2103258308 hasConcept C141071460 @default.
• W2103258308 hasConcept C197934379 @default.
• W2103258308 hasConcept C2776760755 @default.
• W2103258308 hasConcept C2776912625 @default.
• W2103258308 hasConcept C2777138892 @default.
• W2103258308 hasConcept C2777543607 @default.
• W2103258308 hasConcept C2777714996 @default.
• W2103258308 hasConcept C2779134260 @default.
• W2103258308 hasConcept C2779384505 @default.
• W2103258308 hasConcept C2779912601 @default.
• W2103258308 hasConcept C2780252810 @default.
• W2103258308 hasConcept C71924100 @default.
• W2103258308 hasConceptScore W2103258308C126322002 @default.
• W2103258308 hasConceptScore W2103258308C141071460 @default.
• W2103258308 hasConceptScore W2103258308C197934379 @default.
• W2103258308 hasConceptScore W2103258308C2776760755 @default.
• W2103258308 hasConceptScore W2103258308C2776912625 @default.
• W2103258308 hasConceptScore W2103258308C2777138892 @default.
• W2103258308 hasConceptScore W2103258308C2777543607 @default.
• W2103258308 hasConceptScore W2103258308C2777714996 @default.
• W2103258308 hasConceptScore W2103258308C2779134260 @default.
• W2103258308 hasConceptScore W2103258308C2779384505 @default.
• W2103258308 hasConceptScore W2103258308C2779912601 @default.
• W2103258308 hasConceptScore W2103258308C2780252810 @default.
• W2103258308 hasConceptScore W2103258308C71924100 @default.
• W2103258308 hasIssue "11" @default.
• W2103258308 hasLocation W21032583081 @default.
• W2103258308 hasLocation W21032583082 @default.
• W2103258308 hasOpenAccess W2103258308 @default.
• W2103258308 hasPrimaryLocation W21032583081 @default.
• W2103258308 hasRelatedWork W2009454193 @default.
• W2103258308 hasRelatedWork W2072135267 @default.
• W2103258308 hasRelatedWork W2072301382 @default.
• W2103258308 hasRelatedWork W2152381563 @default.
• W2103258308 hasRelatedWork W2159143303 @default.
• W2103258308 hasRelatedWork W2161452915 @default.
• W2103258308 hasRelatedWork W2579455147 @default.
• W2103258308 hasRelatedWork W3000377527 @default.

• next